ProfileGDS5678 / 1455865_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 68% 67% 67% 65% 66% 70% 71% 67% 67% 66% 67% 67% 68% 68% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.2166868
GSM967853U87-EV human glioblastoma xenograft - Control 24.0336567
GSM967854U87-EV human glioblastoma xenograft - Control 34.0528267
GSM967855U87-EV human glioblastoma xenograft - Control 43.8863265
GSM967856U87-EV human glioblastoma xenograft - Control 53.9851866
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.3704870
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.4660171
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.0788167
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.0627267
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.0048666
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.0935167
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.0401867
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.1544368
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.1345768